企業プロフィール
Regeneron Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- REGN
- 取引所:
- NASDAQ
- セクター:
- Antibody Drugs, Biopharma
- 所在地:
- United States
株価パフォーマンス
805.93 USD (+0.30%)
終値
最終更新: 2026年8月17日
63.2B USD
時価総額
株価変動の要因
As of Aug 17, 2026, REGN closed up 0.30% at $805.93. No new same-company headline was identified in the current news window.
企業概要
Integrated Biopharmaceutical Company
Regeneron Pharmaceuticals discovers, develops, manufactures and commercializes medicines across ophthalmology, immunology, oncology, rare disease, cardiovascular medicine and other areas. Its internal technology platforms support a large clinical portfolio and multiple global collaborations.
Retinal Disease Franchise
EYLEA and EYLEA HD are anti-VEGF therapies used in retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema. EYLEA HD offers extended dosing intervals and anchors Regeneron’s ophthalmology business.
Dupixent Collaboration
Dupixent is an IL-4 receptor alpha antibody developed globally with Sanofi across type 2 inflammatory diseases. Its indications span dermatologic, respiratory and allergic conditions, including recent expansions into pediatric chronic spontaneous urticaria and allergic fungal rhinosinusitis.
Oncology Pipeline
Regeneron commercializes the PD-1 antibody Libtayo and is developing fianlimab, a LAG-3 antibody, with cemiplimab in metastatic and adjuvant melanoma. The company’s oncology strategy combines proprietary antibodies across complementary immune pathways.
Rare-Disease Medicines
Otarmeni is an approved AAV gene therapy for OTOF-related severe-to-profound hearing loss. Garetosmab, an Activin A antibody, is under regulatory review for fibrodysplasia ossificans progressiva, while cemdisiran is an siRNA therapy submitted for myasthenia gravis.
Cardiovascular and Metabolic Programs
REGN7508 and REGN9933 are Factor XI antibodies in Phase 3 development for thrombosis prevention. Mibavademab is a leptin-receptor agonist antibody in Phase 3 testing for monogenic obesity.
今後のカタリスト
- FDA decisions on EYLEA HD prefilled-syringe manufacturing applications anticipated in the second quarter of 2026.
- Phase 3 first-line metastatic-melanoma results for fianlimab plus cemiplimab expected in the second quarter of 2026.
- Second interim or final analysis of the adjuvant-melanoma fianlimab study expected in the second half of 2026.
- FDA action on the garetosmab BLA for FOP targeted for August 2026.
- FDA filing acceptance for cemdisiran anticipated in the second quarter of 2026, with a decision expected in the fourth quarter.
- Additional Phase 3 Factor XI antibody studies planned later in 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。